Nexalin Technology Inc. logo

Nexalin Technology Inc.(NXL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.48
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NXL

11/13/2026: NXL (1-star) is currently NOT-A-BUY. Pass it for now.

Nexalin Technology Inc. is an early-stage medical device company focused on developing non-invasive neurostimulation therapies for mental health and neurological conditions. Its primary strength lies in its patented 15Hz technology, which offers a potentially drug-free alternative to current treatments. The company's investment story centers on the success of its clinical trials and future FDA approvals for high-demand applications like anxiety and Alzheimer's disease. However, Nexalin faces significant execution, competitive, and regulatory risks, alongside limited current revenue. The stock is generally suited for aggressive growth investors capable of managing high volatility, and potential shareholders should closely monitor clinical trial updates and reimbursement progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile the technology sector is high-growth, Nexalin represents a high-risk early-stage opportunity.
Momentum investorStrong fit while signal remains positiveMomentum investors may find the stock attractive during clinical news-driven breakouts.
Value investorWeak fitThe company lacks the earnings and fundamental stability required for traditional value strategies.
Dividend investorWeak fitNexalin is a cash-burning growth company that pays no dividends.
Low-risk investorWeak fitHigh volatility and operational uncertainty make this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap medical technology stocks are prone to rapid and extreme price movements based on news flow.
Valuation riskHighValuations are highly speculative as they are based on future clinical and regulatory success rather than current earnings.
Competition risk (Neurostimulation)Medium / highWell-funded competitors with established market presence pose a major threat to gaining market share.
Business qualityMediumThe company is at an early development stage with an unproven commercial model.
Dividend incomeLow / noneThere is no income potential as the company reinvests all capital.
Execution riskHighThe business depends entirely on successful clinical outcomes and regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.83M USD
Price to earnings Ratio -
1Y Target Price 15
Price to earnings Ratio -
1Y Target Price 15
Volume (30-day avg) 71.2K shares
Beta 4.34
52 Weeks Range 1.31 - 33.60
Updated Date 11/14/2026
52 Weeks Range 1.31 - 33.60
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -13.69

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 338.55%
Avg. Invested days 16
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
NXL receives a 3-star rating based on the available scored pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
NXL has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+78.8%) is partially offset by negative earnings growth (-8.1%), weak cash generation (FCF margin -1643.5%), weak profitability (net margin -2725.8%).

Financial Health Rating

★★★★★
NXL's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 73.6%). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is NXL's strongest growth driver at +78.8% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-8.1%, negative) and free-cash-flow growth (-20.5%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 1.9% and approximately 53.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 14.27% supports management-shareholder alignment.

Top 5 Institutional Investors

Geode Capital Management, LLC 0.44%
Vanguard Capital Management, LLC 0.40%
Jane Street Group LLC 0.21%
Vanguard Fiduciary Trust Co 0.16%
State Street Corp 0.10%

Unit Economics (Per $1K Revenue)

★★★★★
NXL generates approximately $797 of gross profit, $-27,817 of operating income, and $-16,435 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.01% (Tax Credit)

Quantitative Style Profile

★★★★★
NXL has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Neurostimulation SystemsSale of Nexalin devices and recurring fees for related support or consumables.The company makes money by selling medical hardware used for treating mental health.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2.26M
Price to Sales(TTM) 8.43
Enterprise Value 2.26M
Price to Sales(TTM) 8.43
Enterprise Value to Revenue 8.16
Enterprise Value to EBITDA 0.02
Shares Outstanding 1.24M
Shares Floating 661.10K
Shares Outstanding 1.24M
Shares Floating 661.10K
Percent Insiders 14.27
Percent Institutions 1.91

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.